Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration

Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration

Abstract Background Anti-vascular endothelial growth factor (VEGF) therapy is currently the most effective therapy of exudative age-related macular degeneration (AMD). The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with e...

Full description

Bibliographic Details
Main Authors: Regina Lukacs, Miklos Schneider, Zoltan Zsolt Nagy, Gabor Laszlo Sandor, Kinga Kaan, Antonia Asztalos, Lajos Enyedi, Gyorgy Pek, Gyorgy Barcsay, Antal Szabo, Agnes Borbandy, Illes Kovacs, Miklos Denes Resch, Andras Papp
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Ophthalmology
Subjects:
Exudative
Wet
Age-related macular degeneration
AMD
Retina
Macula
Online Access:https://doi.org/10.1186/s12886-023-02843-2

Internet

https://doi.org/10.1186/s12886-023-02843-2

Similar Items